Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case Series.

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-09-13 DOI:10.1016/j.clinthera.2025.08.014

Lili Jiang, Jiaoyan Chen, Jurong Yang, Yan Sun, Mingyue Hou, Yunyan Wang

引用次数: 0

Abstract

Purpose: This is a series of reports describing how increasing the time interval between the administration of nafamostat mesylate (NM) and levocarnitine can suppress adverse reactions in maintenance hemodialysis patients after medication.

Methods: Clinical assessments and medical record collection were conducted by nephrologists and nurses, while laboratory tests were performed by specialist doctors.

Findings: Increasing the time interval between NM and levocarnitine administration (15-25 minutes) reduced adverse drug reactions, including nausea and vomiting, in 4 patients.

Implications: This may provide clinical doctors with new insights and research directions when using levocarnitine and NM for dialysis treatment.

查看原文本刊更多论文

增加透析患者同时使用甲磺酸纳莫他和左卡尼汀后的时间间隔抑制不良反应：病例系列。

目的：这是一系列报道，描述了增加甲磺酸那莫他酯（NM）和左卡尼汀给药之间的时间间隔如何抑制维持性血液透析患者用药后的不良反应。方法：临床评估和病历收集由肾内科医生和护士进行，实验室检查由专科医生进行。结果：增加NM与左卡尼汀给药的时间间隔（15-25分钟）减少了4例患者的药物不良反应，包括恶心和呕吐。意义：这可能为临床医生使用左卡尼汀和NM进行透析治疗提供新的见解和研究方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.